MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) is developing an AI-driven voice analysis platform designed to detect drug and alcohol intoxication in real time, addressing growing demand for faster, scalable and noninvasive impairment detection across workplace safety, healthcare and public safety markets, according to a press release.
By leveraging speech as a diagnostic biomarker, the company is pursuing a differentiated approach to multisubstance intoxication detection within an evolving AI healthcare landscape that includes HeartFlow Inc. (NASDAQ: HTFL), Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Tempus AI Inc. (NASDAQ: TEM) and Butterfly Network Inc. (NYSE: BFLY). As substance-use patterns evolve and the limitations of traditional testing methods become increasingly apparent, AI-enabled diagnostics are gaining momentum as a potential next-generation solution for real-time decision-making and risk management.
MindBio is targeting large commercial opportunities spanning workplace compliance, telehealth and consumer health applications, positioning its voice-based platform within a broader transformation toward accessible, data-driven diagnostic technologies. The company’s AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
The announcement comes as the real-time diagnostics market expands, driven by the need for rapid, noninvasive testing methods that can be deployed in various settings. Traditional methods such as breathalyzers and blood tests have limitations in terms of scalability and convenience, making voice-based AI a promising alternative. MindBio’s platform could provide immediate results without requiring specialized equipment or trained personnel, potentially reducing costs and improving safety outcomes.
For more information, the full press release is available at https://ibn.fm/BZOb2. The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF.
MindBio Therapeutics is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company’s technology aims to provide a noninvasive, scalable solution for impairment detection, with potential applications across multiple industries.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is MindBio Therapeutics Develops AI Voice-Based Platform for Real-Time Intoxication Detection.